Oncotarget

Research Perspectives:

From rapalogs to anti-aging formula

Mikhail V. Blagosklonny _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:35492-35507. https://doi.org/10.18632/oncotarget.18033

Metrics: PDF 2542 views  |   HTML 12745 views  |   ?  


Abstract

Mikhail V. Blagosklonny1

1 Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA

Correspondence to:

Mikhail V. Blagosklonny, email:

email:

 

Keywords: lifespan, longevity, rejuvenation, health, diseases

Received: February 17, 2017 Accepted: April 30, 2017 Published: May 22, 2017

Abstract

Inhibitors of mTOR, including clinically available rapalogs such as rapamycin (Sirolimus) and Everolimus, are gerosuppressants, which suppress cellular senescence. Rapamycin slows aging and extends life span in a variety of species from worm to mammals. Rapalogs can prevent age-related diseases, including cancer, atherosclerosis, obesity, neurodegeneration and retinopathy and potentially rejuvenate stem cells, immunity and metabolism. Here, I further suggest how rapamycin can be combined with metformin, inhibitors of angiotensin II signaling (Losartan, Lisinopril), statins (simvastatin, atorvastatin), propranolol, aspirin and a PDE5 inhibitor. Rational combinations of these drugs with physical exercise and an anti-aging diet (Koschei formula) can maximize their anti-aging effects and decrease side effects.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18033